Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-01-29
2008-01-29
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S389100, C424S130100
Reexamination Certificate
active
07323548
ABSTRACT:
Proteins capable of modulating the function of FAS/APO1 are provided. The proteins may be prepared by culturing a host cell transformed with a vector containing the DNA encoding such a protein under suitable conditions and isolating the protein.
REFERENCES:
patent: 4889806 (1989-12-01), Olson et al.
patent: WO 96/12735 (1996-05-01), None
patent: WO 96/30404 (1996-10-01), None
patent: WO 96/31603 (1996-10-01), None
patent: WO 96/36730 (1996-11-01), None
Komada et al (Blood, 86(10): 3848-3860).
Gura (Science, 1997, 278:1041-1042.).
Ahn et al, “The structural and functional diversity of dystrophin.”Nature Genetics. 3(4):283-91 (1993).
Baker et al, “Transducers of life and death: TNF receptor superfamily and associated proteins”,Oncogene12(1):1-9 91996.
Blau et al, “Gene Therapy—A Novel Form of Drug Delivery”New Engl J Med2:333(18):1204-7 (1995).
Boldin et al, “Genbank Sequence Database (Accession X84709) and MPSRCH search report.” us-09-824-134-1.rge (1995).
Boldin et al, “A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain”,J Biol Chem270(14):7795-7798 (1995).
Boldin et al, “Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1—and TNF Receptor-Induced Cell Death”,Cell85(6):803-815 (1996).
Branch, “A Good Antisense Molecule is Hard to Find.”Trends Biochem Sci. 23(2):45-50 (1998).
Burgess et al, “Actvities of Heparin-binding (Acidiic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue.”Journal of Cell Biology11:2129-2138 (1990).
Cawthon et al, “cDNA Sequence and Genomic Structure ofEVI2B, a Gene Lying within an Intron of the Neurofibromatosis Type 1 Gene.”Genomics9(3):446-60, 1991.
Chinnaiyan et al, “FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiated apoptosis”,Cell81:505-512 (1995).
Clement et al, “Fas and Tumor Necrosis Factor Receptor Mediated Cell Death: Similarities and Distinctions”,J Exp Med180:557-567 (1994).
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success.”Science, 270: 404-410 (1995).
Curti, “Physical barriers to drug delivery in tumors.”Cri Rev in Oncology/hematology. 14:29-39 (1993).
Deonarain, “Ligand-targeted receptor-mediated vectors for gene deliver.”Expert Opin Ther Pat. 8:53-69 (1998).
Freshney,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., New York: p. 4 (1983).
Gillies et al, “Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.”Human Antibodies and Hybridomas. 1(1):47-54 (1990).
Gura, “Systems for Identifying New Drugs Are Often Faulty.”Science278:1041-1042 (1997).
Harris et al, “Polycystic Kidney Disease 1: Identification and Analysis of the Primary Defect.”The Am Society of Nephrology6:1125-33 (1995).
Hartwell et al, “Integrating Genetic Approaches into the Discovery of Anticancer Drugs.”Science278:1064-1068 (1997).
Jain, “Barriers to Drug Delivery in Solid Tumors.”Sci Am, 271:58-65 (1994).
Lazar et al, “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities.” 8:1247-1252 (1988).
Marshall, “Gene Therapy's Growing Pains”,Science25:269(5227): 1050-5 (1995).
Miller, “Targeted vectors for gene therapy.”FASEB J. 9:190-199 (1995).
Nagata et al, “Fas and Fas ligand: A death factor and its receptor”,Advances in Immunology57:129-144 (1994).
Rudert et al,Biohysical and biophysical research communications, 204(3):1102-1110 (1994).
Sambrook et al,Molecular Cloning, A Laboratory Manual. 2ndEd., Cold Spring Harbor Press, Cold Spring Harbor, 16.3-16.4 (1989(.
Song et al, “Aggregation of the Intracellular Domain of the Type 1 Tumor Necrosis Receptor Defined by the Two-hybrid System”,J biol Chem269(36):22492-22495 (1994).
Tao et al, “Studies of Aglycosylated Chimeric Mouse-Human IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region.”The Journal of Immunology.
Verma, “Gene therapy- promises, problems and prospects.”Nature. 389:239-242 (1997).
GenBank Accession No. Q13158: “FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis”, Aug. 18, 2002.
GenBank Accession No. U24231: “Human Fas-assoiciating death domain-containing protein mRNA, complete cds”, Aug. 18, 2002.
GenBank Accession No. Q15121: “Astrocytic phosphoprotein”, Nov. 1, 1997.
GenBank Accession No. X86809: “H. sapiensmRNA for major astrocytic phosphoprotein PEA-15”, Jul. 23, 1996.
GenBank Accession No. P16157: “Ankyrin 1 (Erythrocyte Ankyrin)”, Apr. 1, 1990.
GenBank Accession No. P08138: “Low-affinity nerve growth factor receptor precursor (NGF receptor)”, Aug. 1, 1988.
GenBank Accession No. P19438: “Tumor necrosis factor receptor 1 precursor (Tumor necrosis factor binding protein 1)”, Feb. 1, 1991.
GenBank Accession No. NP—002459: “Myeloid differentiation primary response gene (88)”, Mar. 19, 1999.
GenBank Accession No. P22366: “Myeloid differentiation primary response protein MYD88”, Aug. 1, 1991.
GenBank Accession No. P35445: “FASL Receptor precursor (apoptosis-mediating surface antigen FAS) (APO-1 Antigen) (CD95 Antigen)”, May 1, 1992.
GenBank Accession No. P53355: “Death-associated protein kinase 1 (DAP kinase 1)”, Oct. 1, 1996.
MPSRCH search report, us-09-824-134-1.rge: 4-5 (2002).
MPSRCH search report, us-09-824-134-2.rpr:1 (2002).
Boldin Mark
Mett Igor
Varfolomeev Eugene
Wallach David
Aeder Sean E
Browdy and Neimark PLLC
Yeda Research and Development Co. Ltd.
Yu Misook
LandOfFree
Modulators of the function of FAS/APO1 receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of the function of FAS/APO1 receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of the function of FAS/APO1 receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2811069